echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Another drug company! The first shares of private hospitals are on the verge of de-listed

    Another drug company! The first shares of private hospitals are on the verge of de-listed

    • Last Update: 2021-02-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Another pharmaceutical enterprises to sell the first private hospital "private hospital first share" Hengkang medical assets reorganization and new changes.
    On the 12th day, the listed company Yiyi Pharmaceuticals disclosed that it intends to transfer its own funds of 880 million yuan to Huabao Trust to hold the priority property shares of the two merger and acquisition funds of Jingfu Huatze and Jingfu Huayue.
    Said that the purchase of two fund priority property shares, access to its quality medical services assets, in line with the company's strategic objectives.
    It is understood that the excellent medical service assets, namely, Beijing Fuhua Yue holds 99% of the shares of Lancao First Hospital, Lancao Yang Hospital, Lancao Oriental Hospital;
    the first half of 2020, the four hospitals reported total revenue of RMB438 million, accounting for 40% of Hengkang Medical Sector revenue, and contributed about RMB39.23 million in net profit.
    according to the 21st Century Economic Report, when the two funds were set up in Beijing Fuhua Yue and Jingfu Huace, Hengkang Medical and the real controller, Yu Wenbin, signed a strict bottom-up agreement.
    agreement stipulates that when the fund is liquidated, if neither Minsheng Trust and Huabao Trust achieve the target rate of return, Yu Wenbin has the obligation to make up the difference, and Hengkang Medical has the obligation to acquire the shares of the fund held by Minsheng Trust and Huabao Trust.
    , the two funds have reached the exit period, but their acquisition of hospital assets losses are serious.
    it is also understood that Yiyi Pharmaceuticals is not the first time to lay out the medical field.
    It is understood that as early as 2004, Yiyi Pharmaceuticals acquired the People's Hospital of Mannan County, in 2016, Yiyi Pharmaceuticals acquired a 53% stake in Huainan Chaoyang Hospital for 610 million yuan, and in 2017, Yiyi Pharmaceuticals received a 90% stake in Mianyang Fu Lin Hospital for 130 million yuan.
    2018, Yiyi Pharmaceuticals acquired Huainan Chaoyang Hospital, which has been under three years old, for 660 million yuan, to stop the decline and ease the financial pressure.
    the transfer is completed, the company no longer holds a stake in the hospital management company.
    addition, Yiyi Pharmaceuticals has established a group of doctors.
    The 2019 China Physicians Group Development Report, written by The Medical Profession Media in shanghai 2019 in cooperation with the Shanghai Xuanda Non-Public Hospital Management Research Institute, shows that Yiyi Pharmaceuticals announced in 2016 that it had established six companies under the name "Oncologist Group" in several provinces, but soon found it difficult.
    april 2019, Yiyi Pharmaceuticals announced that it would sell its stake in the Doctors Group and no longer hold a stake in the Doctors Group.
    more than one listed pharmaceutical company is eyeing Hengkang Medical. It is worth noting that Yiyi Pharmaceuticals is not the only company that wants to enter Hengkang Medical Asset Restructuring.
    according to Hengkang Medical's recent asset restructuring announcement, Hai wang Group, a pharmaceutical company from Shenzhen, led the coordination of Hengkang Medical restructuring as an industry investor, clearly will help Hengkang Medical solve the debt problem.
    public information shows that Sea King Group is a 2020 China's top 500 private enterprises 131 pharmaceutical enterprises, currently owned by Nep king biology, Nep king Intron, Nepational Star three listed companies.
    Under the agreement, Hai wang group holding subsidiary Health Gold Control will be assigned two shares of the merger fund by December 3 this year, and ensure that Huabao Trust and Minsheng Trust stop the liquidation of the two merger funds, while exempting it from the penalty interest on Hengkang Medical and other ways to ensure that Hengkang Medical will be profitable by 2020.
    After the aforementioned debt settlement, the voting rights corresponding to the 19.90% stake in Hengkang Medical intended to be held by Yu Wenbin will be irrevocablely delegated to Hai wang group, which will take control of Hengkang Medical until the completion of the restructuring process.
    on the verge of de-market! Aggressive expansion costly It is understood that Hengkang Medical's predecessor is Gansu Chinese medicine enterprises "unique", in 2008, listed on the Shenzhen Stock Exchange, the real controller Yin Wenbin from 2009 onwards, for 9 consecutive years by Hurun 100 rich listed as the richest in Gansu Province.
    the general trend of medical reform, in 2013, the unique announcement of the name hengkang medical, began to enter the medical service industry, planning to build "oncology treatment, high-end maternity" medical layout.
    after 2014, Hengkang Medical began a large-scale merger and acquisition expansion, to 2017 a total of 19 hospitals and medical institutions, of which 12 hospitals were acquired as wholisted acquisitions, once by the capital market as the "first private hospital shares."
    , however, after aggressive expansion, Hang Seng's health-care debt has increased.
    annual report shows that Hengkang Medical made a profit of 223 million yuan in 2017 and suddenly lost 1,388 million yuan in 2018, further widening its 2019 loss to 2,498 million yuan.
    May 2020, Hengkang Medical's second consecutive year of losses was implemented by the Shenzhen Stock Exchange.
    is Hengkang Medical, known as the first unit of private medical care, in the mire? Some analysts pointed out that the large-scale mergers and acquisitions of hospitals by the medical industry reform and their own poor management, performance is not up to standard and bring about by the impairment of goodwill is an important reason for operating losses.
    , Hengkang Medical has had to sell its unprofitable assets to ease cash flow pressures.
    has disposed of stakes in 10 subsidiaries in 2019 alone.
    take Dalian Liaoyu Hospital as an example.
    December 2, Hengkang Medical intends to transfer 100% of the underlying interest in the hospital for $90 million.
    in 2014, Hengkang Medical acquired 100% property rights in Dalian Liaoyu Hospital at a transaction price of RMB127.8041 million.
    Shing that the acquisition is a failure for Hengkang Medical, but in order to preserve the shell resources of listed companies, not to be de-listed, selling loss-making hospitals and even profitable hospitals has become a step that Hengkang Medical has to take.
    health care, which is on the brink of de-marketing, can get out of the mire is worth paying attention to, and the heavy cost of its blind expansion of medical services is worth thinking about between medical investors.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.